Published in Women's Health Weekly, June 10th, 2004
This new approach combines Sysmex's flow cytometry technology, Matritech's patented NMP179 protein biomarker and other technologies incorporated by Sysmex to perform rapid, highly detailed cell-by-cell analysis for cervical cancer.
Current Pap smear technology only looks at a percentage of cells collected. Sysmex expects to bring this automated cervical cancer testing system to the market by 2006.
"The combination of our proprietary protein and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly